Cargando…
TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718945/ https://www.ncbi.nlm.nih.gov/pubmed/33025742 http://dx.doi.org/10.1002/1878-0261.12814 |
_version_ | 1783619591151288320 |
---|---|
author | Maddalena, Francesca Condelli, Valentina Matassa, Danilo Swann Pacelli, Consiglia Scrima, Rosella Lettini, Giacomo Li Bergolis, Valeria Pietrafesa, Michele Crispo, Fabiana Piscazzi, Annamaria Storto, Giovanni Capitanio, Nazzareno Esposito, Franca Landriscina, Matteo |
author_facet | Maddalena, Francesca Condelli, Valentina Matassa, Danilo Swann Pacelli, Consiglia Scrima, Rosella Lettini, Giacomo Li Bergolis, Valeria Pietrafesa, Michele Crispo, Fabiana Piscazzi, Annamaria Storto, Giovanni Capitanio, Nazzareno Esposito, Franca Landriscina, Matteo |
author_sort | Maddalena, Francesca |
collection | PubMed |
description | Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic stress. The mechanism by which TRAP1 regulates glycolytic metabolism and the relevance of this regulation in resistance to EGFR inhibitors were investigated in patient‐derived CRC spheres, human CRC cells, samples, and patients. A linear correlation was observed between TRAP1 levels and (18)F‐fluoro‐2‐deoxy‐glucose ((18)F‐FDG) uptake upon PET scan or GLUT1 expression in human CRCs. Consistently, TRAP1 enhances GLUT1 expression, glucose uptake, and lactate production and downregulates OXPHOS in CRC patient‐derived spheroids and cell lines. Mechanistically, TRAP1 maximizes lactate production to balance low OXPHOS through the regulation of the glycolytic enzyme phosphofructokinase‐1 (PFK1); this depends on the interaction between TRAP1 and PFK1, which favors PFK1 glycolytic activity and prevents its ubiquitination/degradation. By contrast, TRAP1/PFK1 interaction is lost in conditions of enhanced OXPHOS, which results in loss of TRAP1 regulation of PFK1 activity and lactate production. Notably, TRAP1 regulation of glycolysis is involved in resistance of RAS‐wild‐type CRCs to EGFR monoclonals. Indeed, either TRAP1 upregulation or high glycolytic metabolism impairs cetuximab activity in vitro, whereas TRAP1 targeting and/or inhibition of glycolytic pathway enhances cell response to cetuximab. Finally, a linear correlation between (18)F‐FDG PET uptake and poor response to cetuximab in first‐line therapy in human metastatic CRCs was observed. These results suggest that TRAP1 is a key determinant of CRC metabolic rewiring and favors resistance to EGFR inhibitors through regulation of glycolytic metabolism. |
format | Online Article Text |
id | pubmed-7718945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77189452020-12-11 TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas Maddalena, Francesca Condelli, Valentina Matassa, Danilo Swann Pacelli, Consiglia Scrima, Rosella Lettini, Giacomo Li Bergolis, Valeria Pietrafesa, Michele Crispo, Fabiana Piscazzi, Annamaria Storto, Giovanni Capitanio, Nazzareno Esposito, Franca Landriscina, Matteo Mol Oncol Research Articles Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic stress. The mechanism by which TRAP1 regulates glycolytic metabolism and the relevance of this regulation in resistance to EGFR inhibitors were investigated in patient‐derived CRC spheres, human CRC cells, samples, and patients. A linear correlation was observed between TRAP1 levels and (18)F‐fluoro‐2‐deoxy‐glucose ((18)F‐FDG) uptake upon PET scan or GLUT1 expression in human CRCs. Consistently, TRAP1 enhances GLUT1 expression, glucose uptake, and lactate production and downregulates OXPHOS in CRC patient‐derived spheroids and cell lines. Mechanistically, TRAP1 maximizes lactate production to balance low OXPHOS through the regulation of the glycolytic enzyme phosphofructokinase‐1 (PFK1); this depends on the interaction between TRAP1 and PFK1, which favors PFK1 glycolytic activity and prevents its ubiquitination/degradation. By contrast, TRAP1/PFK1 interaction is lost in conditions of enhanced OXPHOS, which results in loss of TRAP1 regulation of PFK1 activity and lactate production. Notably, TRAP1 regulation of glycolysis is involved in resistance of RAS‐wild‐type CRCs to EGFR monoclonals. Indeed, either TRAP1 upregulation or high glycolytic metabolism impairs cetuximab activity in vitro, whereas TRAP1 targeting and/or inhibition of glycolytic pathway enhances cell response to cetuximab. Finally, a linear correlation between (18)F‐FDG PET uptake and poor response to cetuximab in first‐line therapy in human metastatic CRCs was observed. These results suggest that TRAP1 is a key determinant of CRC metabolic rewiring and favors resistance to EGFR inhibitors through regulation of glycolytic metabolism. John Wiley and Sons Inc. 2020-10-30 2020-12 /pmc/articles/PMC7718945/ /pubmed/33025742 http://dx.doi.org/10.1002/1878-0261.12814 Text en © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Maddalena, Francesca Condelli, Valentina Matassa, Danilo Swann Pacelli, Consiglia Scrima, Rosella Lettini, Giacomo Li Bergolis, Valeria Pietrafesa, Michele Crispo, Fabiana Piscazzi, Annamaria Storto, Giovanni Capitanio, Nazzareno Esposito, Franca Landriscina, Matteo TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas |
title | TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas |
title_full | TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas |
title_fullStr | TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas |
title_full_unstemmed | TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas |
title_short | TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas |
title_sort | trap1 enhances warburg metabolism through modulation of pfk1 expression/activity and favors resistance to egfr inhibitors in human colorectal carcinomas |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718945/ https://www.ncbi.nlm.nih.gov/pubmed/33025742 http://dx.doi.org/10.1002/1878-0261.12814 |
work_keys_str_mv | AT maddalenafrancesca trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT condellivalentina trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT matassadaniloswann trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT pacelliconsiglia trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT scrimarosella trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT lettinigiacomo trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT libergolisvaleria trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT pietrafesamichele trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT crispofabiana trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT piscazziannamaria trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT stortogiovanni trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT capitanionazzareno trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT espositofranca trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas AT landriscinamatteo trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas |